Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07TQV
|
|||
Former ID |
DAP000167
|
|||
Drug Name |
Lamivudine
|
|||
Synonyms |
lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic HBV infection [ICD-11: 1E51.0Z] | Approved | [1] | |
Human immunodeficiency virus infection [ICD-11: 1C62] | Approved | [1] | ||
Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Approved | [2] | ||
Therapeutic Class |
Anti-HIV Agents
|
|||
Company |
Glaxo Smith Kline Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C8H11N3O3S
|
|||
Canonical SMILES |
C1C(OC(S1)CO)N2C=CC(=NC2=O)N
|
|||
InChI |
1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
|
|||
InChIKey |
JTEGQNOMFQHVDC-NKWVEPMBSA-N
|
|||
CAS Number |
CAS 134678-17-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9277, 596236, 601313, 643736, 811475, 3727051, 3727058, 7847419, 7979719, 8187080, 11528367, 12014700, 12016245, 14798125, 15121620, 24277302, 26719826, 29215254, 43118163, 46386600, 46507855, 49681736, 50140269, 57314135, 81093205, 85279382, 87560180, 92308311, 92712464, 92729822, 93166191, 103195019, 103977094, 104170203, 104253324, 104321740, 117588081, 118048664, 121362453, 124658974, 124757443, 124892101, 125164247, 126584422, 126592947, 126625491, 126656696, 126665392, 127310181, 127310182
|
|||
ChEBI ID |
CHEBI:63577
|
|||
ADReCS Drug ID | BADD_D01242 | |||
SuperDrug ATC ID |
J05AF05
|
|||
SuperDrug CAS ID |
cas=134678174
|
Drug Resistance Mutation (DRM) | Top | |||
---|---|---|---|---|
DRM | DRM Info |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.